Galderma Group (SWX:GALD) Following China Study Win Is The Pullback A Valuation Opening

Galderma Group (SWX:GALD) just reported positive topline data from a 162-patient Restylane Volyme study in China for temple hollowing, meeting its primary endpoint and signaling progress in a key aesthetics market.

Against that clinical milestone, Galderma Group’s 1-day share price return of 0.49% to CHF154.05 sits alongside a 30-day share price decline of 8.95% and a 90-day share price decline of 10.75%. The 1-year total shareholder return of 6.33% points to modest longer-term gains and suggests a stock where short-term momentum has cooled even as the broader story continues to evolve.

Spot 619 high quality undiscovered gems in dermatology and medical aesthetics that, like Galderma Group, are building momentum around differentiated treatments and under-the-radar clinical data.

Galderma Group has posted fresh clinical data while the share price has cooled over the past quarter. Is the bigger upside still ahead, or was most of it captured before the recent pullback that set up today’s valuation?

Most Popular Narrative: 12% Overvalued

Galderma Group last closed at CHF154.05, while the most followed narrative pegs fair value at CHF137.52. This reflects a view that the current price embeds fairly rich expectations and leaves limited room for missteps in the core aesthetics and Nemluvio franchises.

The emergence and rapid adoption of lower-cost biosimilars and generics, compounded by looming patent expirations on key products such as Restylane, Dysport, and potentially Nemluvio, severely threaten Galderma's branded pricing power and market share, with the knock-on effect of eroding both gross margins and long-term revenue growth.

See why 1 investors see Galderma Group as 12% overvalued.

Result: Fair Value of CHF137.52 (OVERVALUED)

Still, a stronger launch trajectory for Nemluvio or faster take up across injectable aesthetics could quickly challenge the idea that Galderma Group is priced for perfection.

Find out about the key risks to this Galderma Group narrative.

Another View on Galderma Group’s Valuation

The fair ratio tells a different story. Galderma Group trades on a P/E of 50.5x, compared with 33x for peers and a fair ratio of 38.8x. That gap points to richer expectations than both the sector and the model suggest. Is that optimism a buffer or a risk if growth stumbles?

See what the numbers say about this price, find out in our valuation breakdown See what the numbers say about this price — find out in our valuation breakdown.

Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Galderma Group for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 184 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.

Next Steps

Sentiment around Galderma Group is mixed, so do not wait for consensus to solidify before you look at the underlying metrics yourself. To see what investors view as the bright spots that support this thesis, review the 4 key rewards.

Looking for more ideas beyond Galderma Group?

If you only stop at Galderma Group, you risk missing other opportunities that could better match your goals and tolerance for risk.

• Target resilience first by scanning 104 resilient stocks with low risk scores that aim to balance return potential with a focus on steadier risk profiles.
• Hunt for mispriced quality using the 184 high quality undervalued stocks and see which businesses the data suggests may be trading below their fundamentals.
• Build your watchlist around strength by filtering for a list of solid balance sheet and fundamentals (194 results) that can better withstand shocks and funding pressure.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com